CL2023002064A1 - Derivados de ácido urólico sintético y métodos de uso de estos - Google Patents
Derivados de ácido urólico sintético y métodos de uso de estosInfo
- Publication number
- CL2023002064A1 CL2023002064A1 CL2023002064A CL2023002064A CL2023002064A1 CL 2023002064 A1 CL2023002064 A1 CL 2023002064A1 CL 2023002064 A CL2023002064 A CL 2023002064A CL 2023002064 A CL2023002064 A CL 2023002064A CL 2023002064 A1 CL2023002064 A1 CL 2023002064A1
- Authority
- CL
- Chile
- Prior art keywords
- urolic
- synthetic
- methods
- acid derivatives
- compounds
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163199694P | 2021-01-18 | 2021-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002064A1 true CL2023002064A1 (es) | 2023-12-29 |
Family
ID=80222334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002064A CL2023002064A1 (es) | 2021-01-18 | 2023-07-14 | Derivados de ácido urólico sintético y métodos de uso de estos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240140986A1 (https=) |
| EP (1) | EP4277916A1 (https=) |
| JP (1) | JP2024504637A (https=) |
| KR (1) | KR20230147077A (https=) |
| CN (1) | CN117015548A (https=) |
| AU (1) | AU2022208727A1 (https=) |
| CA (1) | CA3204434A1 (https=) |
| CL (1) | CL2023002064A1 (https=) |
| CO (1) | CO2023010422A2 (https=) |
| IL (1) | IL304530A (https=) |
| MX (1) | MX2023008454A (https=) |
| PE (1) | PE20231661A1 (https=) |
| TW (1) | TW202245795A (https=) |
| WO (1) | WO2022155614A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121794280A (zh) * | 2023-07-28 | 2026-04-03 | 里亚塔医药控股有限责任公司 | 用于制备三萜类衍生物的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907423A2 (pt) | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| MX2010011439A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17. |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| KR101713140B1 (ko) * | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| MX348862B (es) | 2011-03-11 | 2017-07-03 | Reata Pharmaceuticals Inc | Derivados c4-monometil triterpenoides y sus metodos de uso. |
| TWI623548B (zh) * | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法 |
| WO2013188818A1 (en) * | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| JP6243428B2 (ja) * | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| SMT201700501T1 (it) | 2012-09-10 | 2017-11-15 | Reata Pharmaceuticals Inc | Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi |
| AR096046A1 (es) * | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| JP7074674B2 (ja) * | 2015-09-23 | 2022-05-24 | リアタ ファーマシューティカルズ インコーポレイテッド | Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体 |
| CN110198718B (zh) * | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
| MX2021003643A (es) * | 2018-09-28 | 2021-08-19 | Sichuan Haisco Pharmaceutical Co Ltd | Derivados de terpenoides y usos de los mismos. |
-
2022
- 2022-01-18 MX MX2023008454A patent/MX2023008454A/es unknown
- 2022-01-18 JP JP2023542885A patent/JP2024504637A/ja active Pending
- 2022-01-18 US US18/261,732 patent/US20240140986A1/en active Pending
- 2022-01-18 AU AU2022208727A patent/AU2022208727A1/en active Pending
- 2022-01-18 EP EP22703206.7A patent/EP4277916A1/en active Pending
- 2022-01-18 TW TW111102086A patent/TW202245795A/zh unknown
- 2022-01-18 CN CN202280019965.8A patent/CN117015548A/zh active Pending
- 2022-01-18 KR KR1020237028003A patent/KR20230147077A/ko active Pending
- 2022-01-18 PE PE2023002112A patent/PE20231661A1/es unknown
- 2022-01-18 CA CA3204434A patent/CA3204434A1/en active Pending
- 2022-01-18 WO PCT/US2022/012831 patent/WO2022155614A1/en not_active Ceased
-
2023
- 2023-07-14 CL CL2023002064A patent/CL2023002064A1/es unknown
- 2023-07-17 IL IL304530A patent/IL304530A/en unknown
- 2023-08-09 CO CONC2023/0010422A patent/CO2023010422A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20231661A1 (es) | 2023-10-17 |
| KR20230147077A (ko) | 2023-10-20 |
| EP4277916A1 (en) | 2023-11-22 |
| CN117015548A (zh) | 2023-11-07 |
| MX2023008454A (es) | 2023-08-07 |
| IL304530A (en) | 2023-09-01 |
| JP2024504637A (ja) | 2024-02-01 |
| TW202245795A (zh) | 2022-12-01 |
| AU2022208727A1 (en) | 2023-08-03 |
| CA3204434A1 (en) | 2022-07-21 |
| US20240140986A1 (en) | 2024-05-02 |
| CO2023010422A2 (es) | 2023-08-28 |
| WO2022155614A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP24035717A (es) | Compuestos de quinolina como inhibidores de kras | |
| MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| CO2022016899A2 (es) | Moduladores de il-17a | |
| MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
| UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| CL2022001661A1 (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| CL2024001313A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| CL2020002604A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. | |
| MX2017010422A (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| CL2023002064A1 (es) | Derivados de ácido urólico sintético y métodos de uso de estos | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| CL2024001748A1 (es) | Usos de compuestos biciclicos para el tratamiento de enfermedades. | |
| MX2020004871A (es) | Derivados de acido cafeico y sus usos. | |
| CO2025009226A2 (es) | Compuestos terapéuticos | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades |